Protection against severe rotavirus diarrhoea by rhesus rotavirus vaccine in Venezuelan infants.
The efficacy of the rhesus rotavirus vaccine candidate MMU-18006 was evaluated in a longitudinal double-blind field trial in Caracas, Venezuela. 247 infants aged 1-10 months were studied and followed for up to 1 year (201 completed the 1-year surveillance): 123 received a dose of 10(4) plaque-forming units of the vaccine orally and 124 received placebo. 21 episodes of rotavirus diarrhoea were detected, 16 in the controls and 5 in the vaccines: vaccine efficacy against any rotavirus diarrhoea was thus 68%. In the 1-5-month-old group the vaccine efficacy was 93%; only 1 episode of rotavirus diarrhoea was detected in 68 vaccinees and 15 such illnesses were observed in 65 controls (p less than 0.0001). For the entire study group vaccine efficacy was 100% against the most severe rotavirus diarrhoeal episodes.
D000914:Antibodies, Viral / Q000032:analysis; D002986:Clinical Trials as Topic; D003968:Diarrhea, Infantile / Q000382:microbiology / Q000517:prevention & control*; D004311:Double-Blind Method; D006801:Humans; D007223:Infant; D011897:Random Allocation; D012401:Rotavirus / Q000276:immunology; D012400:Rotavirus Infections / Q000517:prevention & control*; D022243:Rotavirus Vaccines; D014611:Vaccination; D014765:Viral Vaccines / Q000276:immunology
D000914:Antibodies, Viral; D022243:Rotavirus Vaccines; D014765:Viral Vaccines; C052014:rhesus rotavirus vaccine